Beigene, Ltd. (NASDAQ:ONC) Director Sells $190,535,020.00 in Stock

Beigene, Ltd. (NASDAQ:ONC) Director Bros. Advisors Lp Baker sold 732,827 shares of the business’s stock in a transaction on Friday, February 28th. The shares were sold at an average price of $260.00, for a total transaction of $190,535,020.00. Following the transaction, the director now owns 730,642 shares of the company’s stock, valued at $189,966,920. This represents a 50.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Beigene Price Performance

Shares of NASDAQ:ONC opened at $271.80 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. Beigene, Ltd. has a 12-month low of $126.97 and a 12-month high of $287.88. The company has a market capitalization of $26.60 billion, a price-to-earnings ratio of -32.99, a P/E/G ratio of 7.73 and a beta of 0.63.

Beigene (NASDAQ:ONC) last posted its earnings results on Thursday, February 27th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.55). Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The firm had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.09 billion. As a group, equities analysts anticipate that Beigene, Ltd. will post -5.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Macquarie boosted their price objective on Beigene from $259.00 to $313.00 and gave the company an “outperform” rating in a report on Friday.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.